Telomir Pharmaceuticals reported a net loss of $3.42 million for the nine months ended September 30, 2026, a significant improvement from the $8.35 million loss in the prior year period. However, the net loss attributable to common stockholders surged to $49.53 million due to a $46.11 million deemed dividend, while cash reserves decreased to $4.52 million from $7.29 million at year-end 2025.
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing through the issuance of 4,843,300 shares of common stock at $1.16 per share. The offering included a $1.0 million investment from existing shareholder John Paul DeJoria and will be used to fund the clinical development of Telomir-Zn for triple-negative breast cancer.
Value
$5.6M
Counterparty
John Paul DeJoria
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir. Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
John Paul DeJoria
“We have been very deliberate about how and when we access the capital markets. Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data in the International Journal of Molecular Sciences demonstrating that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (AMD). The study showed that 14 days of oral treatment significantly improved visual performance, reduced mitochondrial oxidative stress, and increased telomeric DNA content. While the company remains focused on its Phase 1/2 clinical trial for triple-negative breast cancer, these findings suggest the drug's metal-dependent epigenetic biology may have broader applications beyond oncology.
Telomir Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 11, 2026, where shareholders elected four directors to the board. Stockholders also ratified the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.
Counterparty
The Ohio State University College of Veterinary Medicine